Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic β-cell function in hypertensive diabetic patients treated with angiotensin receptor blockers

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 16, Issue 4, 2015, Pages 1001-1009

  Fukui, Kensuke ^a   Kawahito, Hiroyuki ^a   Wakana, Noriyuki ^a   Kikai, Masakazu ^a   Terada, Kensuke ^a   Yamamoto, Keita ^a   Irie, Daisuke ^a   Kato, Taku ^a   Miyagawa, Sonoko ^a   Yamada, Hiroyuki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Angiotensin receptor blockers; Dipeptidyl peptidase 4 inhibitors; Pancreatic cell function; Proinsulin; Type 2 diabetes mellitus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PROINSULIN; SITAGLIPTIN; SULFONYLUREA; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; SULFONYLUREA DERIVATIVE;

ABDOMINAL DISCOMFORT; ADULT; AGED; ARTICLE; CARDIOVASCULAR RESPONSE; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; TREATMENT OUTCOME; VERY ELDERLY; CLINICAL TRIAL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; PATHOLOGY;

AGED; ANGIOTENSIN RECEPTOR ANTAGONISTS; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; HYPERTENSION; HYPOGLYCEMIC AGENTS; INSULIN-SECRETING CELLS; MALE; SITAGLIPTIN PHOSPHATE; SULFONYLUREA COMPOUNDS;

EID: 84952906437     PISSN: 14703203     EISSN: 17528976     Source Type: Journal    
DOI: 10.1177/1470320315587180     Document Type: Article

References (26)

1. Lupi R, Del Prato S,. Beta-cell apoptosis in type 2 diabetes: Quantitative and functional consequences. Diabetes Metab 2008; 34: S56-S64.
2. Rahier J, Guiot Y, Goebbels RM, et al. Pancreatic beta-cell mass in European subjects with type 2 diabetes. Diabetes Obes Metab 2008; 4: 32-42.
3. Kahn SE, Haffner SM, Heise MA, et al.; ADOPT Study Group. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006; 355: 2427-2443.
4. Maedler K, Carr RD, Bosco D, et al. Sulfonylurea induced beta-cell apoptosis in cultured human islets. J Clin Endocrinol Metab 2005; 90: 501-506.
5. Van Genugten RE, van Raalte DH, Diamant M,. Dipeptidyl peptidase-4 inhibitors and preservation of pancreatic islet-cell function: A critical appraisal of the evidence. Diabetes Obes Metab 2012; 14: 101-111.
6. Amori RE, Lau J, Pittas AG,. Efficacy and safety of incretin therapy in type 2 diabetes: Systematic review and meta-analysis. JAMA 2007; 298: 194-206.
7. Dalle S, Burcelin R, Gourdy P,. Specific actions of GLP-1 receptor agonists and DPP4 inhibitors for the treatment of pancreatic β-cell impairments in type 2 diabetes. Cell Signal 2013; 25: 570-579.
8. Drucker DJ,. Incretin action in the pancreas: Potential promise, possible perils, and pathological pitfalls. Diabetes 2013; 62: 3316-3323.
9. Lee YS, Jun HS,. Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 2014; 63: 9-19.
10. Sowers JR, Zemel MB,. Clinical implications of hypertension in the diabetic patient. Am J Hypertens 1990; 3: 415-424.
11. Deedwania PC,. Hypertension and diabetes: New therapeutic options. Arch Intern Med 2000; 160: 1585-1594.
12. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005; 165: 1410-1419.
13. Schmieder RE, Hilgers KF, Schlaich MP, et al. Renin-angiotensin system and cardiovascular risk. Lancet 2007; 369: 1208-1219.
14. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2013; 31: 1281e357.
15. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: Report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014; 311: 507-520.
16. Perlstein TS, Henry RR, Mather KJ, et al. Effect of angiotensin receptor blockade on insulin sensitivity and endothelial function in abdominally obese hypertensive patients with impaired fasting glucose. Clin Sci 2012; 122: 193-202.
17. Aksnes TA, Reims HM, Guptha S, et al. Improved insulin sensitivity with the angiotensin II-receptor blocker losartan in patients with hypertension and other cardiovascular risk factors. J Hum Hypertens 2006; 20: 860-866.
18. Shao J, Iwashita N, Ikeda F, et al. Beneficial effects of candesartan, an angiotensin II type 1 receptor blocker, on beta-cell function and morphology in db/db mice. Biochem Biophys Res Commun 2006; 344: 1224-1233.
19. Madec AM, Cassel R, Dubois S, et al. Losartan, an angiotensin II type 1 receptor blocker, protects human islets from glucotoxicity through the phospholipase C pathway. FASEB J 2013; 27: 5122-5130.
20. Shimizu S, Hosooka T, Matsuda T, et al. DPP4 inhibitor vildagliptin preserves β-cell mass through amelioration of endoplasmic reticulum stress in C/EBPB transgenic mice. J Mol Endocrinol 2012; 49: 125-135.
21. Wang HW, Mizuta M, Saitoh Y, et al. Glucagon-like peptide-1 and candesartan additively improve glucolipotoxicity in pancreatic β-cells. Metabolism 2011; 60: 1081-1089.
22. Charbonnel B, Karasik A, Liu J, et al. Sitagliptin Study 020 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638-2643.
23. Goldstein BJ, Feinglos MN, Lunceford JK, et al.; Sitagliptin 036 Study Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979-1987.
24. DeFronzo RA, Fleck PR, Wilson CA, et al.; Alogliptin Study 010 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: A randomized, double-blind, placebo-controlled study. Diabetes Care 2008; 31: 2315-2317.
25. Aschner P, Kipnes MS, Lunceford JK, et al.; Sitagliptin Study 021 Group. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632-2637.
26. Raz I, Hanefeld M, Xu L, et al.; Sitagliptin Study 023 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564-2571.